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Abstract
Candida albicans, a clinically important dimorphic fungal pathogen that can evade immune attack by masking its cell wall b-
glucan from immune recognition, mutes protective host responses mediated by the Dectin-1 b-glucan receptor on innate
immune cells. Although the ability of C. albicans to switch between a yeast- or hyphal-form is a key virulence determinant,
the role of each morphotype in b-glucan masking during infection and treatment has not been addressed. Here, we show
that during infection of mice, the C. albicans b-glucan is masked initially but becomes exposed later in several organs. At all
measured stages of infection, there is no difference in b-glucan exposure between yeast-form and hyphal cells. We have
previously shown that sub-inhibitory doses of the anti-fungal drug caspofungin can expose b-glucan in vitro, suggesting
that the drug may enhance immune activity during therapy. This report shows that caspofungin also mediates b-glucan
unmasking in vivo. Surprisingly, caspofungin preferentially unmasks filamentous cells, as opposed to yeast form cells, both
in vivo and in vitro. The fungicidal activity of caspofungin in vitro is also filament-biased, as corroborated using yeast-locked
and hyphal-locked mutants. The uncloaking of filaments is not a general effect of anti-fungal drugs, as another anti-fungal
agent does not have this effect. These results highlight the advantage of studying host–pathogen interaction in vivo and
suggest new avenues for drug development.
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Introduction
Candida albicans, a common commensal organism of humans,
has emerged as an important fungal pathogen clinically due to the
immunocompromised status of many patients as well as the
ineffectiveness of current anti-fungal drugs [1]. The immune
system has many pathways for recognizing and responding to C.
albicans, including innate immune Toll-like receptors, lectin
receptors, antibody, complement, and mannose binding lectin
[2]. A major innate immune receptor for C. albicans is Dectin-1, a
lectin that can recognize b-glucan, a unique component of the
fungal cell wall. In vitro analysis shows that Dectin-1 recognizes
fungal b-glucan (comprising glucan polymers with mixed b1,3-
and b1,6- linkages), and signals through unique pathways to
induce phagocytosis, up-regulation of immune killing mechanisms,
and production of pro-inflammatory cytokines [3].
The mechanism of b-glucan signaling through Dectin-1 is
unclear because this signature molecule on Candida and other fungi
is enveloped by a cell wall mannoprotein layer that masks almost
all of the b-glucan from immune recognition and mutes the host
immune response [4,5,6,7,8]. On one hand, the b-glucan masking
observed in vitro runs contrary to an active role for Dectin-1
recognition of b-glucan during infection [8,9,10]. On the other
hand, in vitro Dectin-1 is clearly able to mediate protective
responses to fungi and zymosan, a treated fungal particle with
exposed b-glucan [9,11,12,13,14]. In addition, work in knock-out
mice suggests at least a conditional requirement for Dectin-1 in
resistance to the SC5314 strain of C. albicans, which may be
dependent on mouse strain and/or C. albicans strain [13,14].
An additional complexity at the Candida-host interface is that C.
albicans has several developmental cell types including yeast,
pseudohyphae, and hyphae, each with different modes of
interaction with innate immune cells [15,16]. The ability of C.
albicans to switch between the yeast and filamentous forms is
strongly associated with virulence. Filaments are distinct from
yeast-form cells in cell wall structure, cell wall proteins and
transcriptional programs. In addition, the hyphal form of the
fungus has been shown to cause more tissue damage than the
yeast-form fungus in ex vivo models of candidiasis [17,18,19].
Furthermore, immune recognition of yeast provokes a different
immune response compared to recognition of hyphae [15,20].
Intriguing recent work has suggested that only yeast-form cells
possess exposed b-glucan at a few sites [9], but this has yet to be
shown in vivo.
Although b-glucan can be an important signal for innate
immune cells in vitro, and the b-glucan receptor Dectin-1 protects
against fungal disease in mice, we still understand little of the
dynamics of b-glucan-Dectin-1 interaction during infection or
drug treatment. We have developed a new technique to directly
measure morphotype-specific b-glucan exposure in mouse tissue
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dynamics of b-glucan exposure during infection and during
treatment with the cell wall-directed drug caspofungin. Caspo-
fungin treatment, either in vitro or in vivo, causes dramatic, hyphal-
biased exposure of b-glucan. By contrast, although in the absence
of the drug there is progressive unmasking of b-glucan during
infection, there is no difference between yeast form and hyphal
cells. Our results support a role for Dectin-1 in recognition of C.
albicans during infection and drug therapy and demonstrate a novel
morphotype bias in the action of the anti-fungal caspofungin,
highlighting new avenues for drug development.
Results
Drug-induced b-glucan unmasking and fungicidal
activities are filament biased
The anti-fungal drug caspofungin (CF) unmasks b-glucan at
sub-inhibitory concentrations during growth of Candida albicans in
culture media that promotes either exclusively yeast-form or
hyphal-form growth [8]. During infection, C. albicans grows in
conditions that promote both yeast and hyphal forms [21]. To
study conditions more similar to in vivo growth, we grew C. albicans
in sub-inhibitory concentrations of CF in RPMI media at a
temperature that concurrently permit yeast-, pseudohyphal-, and
hyphal-form growth. Growth at K the minimum inhibitory
concentration (MIC) of CF causes striking b-glucan unmasking, as
assayed with anti-b-glucan antibody specific for b1,3-glucan
(Figure 1A and 1B).
Consistent with our previous work [8], there is very little cell
death during growth in K MIC of CF, as assayed by propidium
iodide staining. This result was further confirmed by using the
WT-GFP strain, engineered to constitutively express yEGFP in the
SC5314 clinical isolate. WT-GFP fluoresces at similar intensity to
CAI4-GFP [22] and grows at wildtype rates (data not shown). The
cytoplasmic GFP fluorescence enables the identification of live
cells, because live cells have a characteristic cytoplasmic pattern of
green fluorescence (see Methods).
Unexpectedly, there is a striking bias in exposure of filaments as
opposed to yeast-form cells—a high percentage of hyphal cells
have exposed b-glucan, whereas only a few yeast-form cells have
exposed b-glucan (Figure 1E). The filament-specific exposure of b-
glucan was also found in several clinical isolates, suggesting this is a
general feature of caspofungin (Figure S1). To ensure that this
differential effect on filaments was not due to persistence of the
initial inoculum of yeast-form cells (which were pre-grown in the
absence of CF), we followed the persistence of these original cells
during CF treatment by marking them with the amine-reactive
dye Alexa fluor 647-succinimidyl ester. As shown in Figure 1C,
treatment of live cells with the dye homogeneously labels all cells in
the inoculum. The label is retained on the surface of the original
dye-tagged cells even when they are grown in hyphal-promoting
conditions (37uC with serum), which results in no loss of label
intensity on the mother cell and no transferral of label to growing
hyphae in those cells (Figure 1D). This suggests that the cell surface
proteins labeled by the amine-reactive Alexa fluor 647 dye are
tightly retained in the cell wall and provide a long-lasting, non-
dispersing mark for following the ancestry of C. albicans cells. We
then used this to ask whether the yeast cells with no exposure are
from the pre-culture or grew in the presence of caspofungin. As
shown in Figure 1E, the majority of yeast-form cells in overnight
cultures have no Alexa label and therefore were newly formed in
the presence of CF. Thus, growth in pseudohyphal or hyphal
form, as compared to yeast-form, predisposes C. albicans to b-
glucan unmasking by CF.
The above data suggest that CF specifically unmasks hyphal
forms. To further test this we utilized C. albicans mutants that grow
exclusively in hyphal- or yeast-form, independent of growth media.
Due to the possibility that any given mutant might show altered
sensitivity unrelated to its morphotypic defect, we chose a variety of
strains. Specifically, we analyzed two mutants locked in filamentous
growth form (tup1D/D [23] and nrg1D/D [24]), two mutants locked
in yeast-form growth (edt1D/D and efg1D/D cph1D/D [25]), and
several wildtype strains (SC5314, CAF2, and WT-GFP). The EDT1
gene, originally isolated based on its requirement for filamentation,
results in constitutive yeast-form growth when deleted (Chen et al,
unpubl. results). When these morphotype specific mutants grown at
sub-inhibitory doses of CF are stained for b-glucan exposure,
filament-locked mutants such as nrg1D/D have exposure similar to
wildtype filamentous cells but yeast-locked cells such as edt1D/D
show little exposure (Figure 1F–1H). The finding that yeast-locked
cells show no b-glucan unmasking at sub-inhibitory CF concentra-
tions supports the conclusion that morphogenesis and sensitivity to
unmasking are linked.
The filament bias of b-glucan exposure by CF raised the
possibility that the drug’s fungicidal activity may also act
preferentially on filamentous cells. To test this, we probed the
efficacy of CF against Candida mutants locked in either the yeast or
filamentous form under conditions that normally permit growth of
both filaments and yeast-form cells. Compared to wild type strains,
mutant filamentous strains consistently show greater drug
sensitivity and yeast-form mutants show greater resistance
(Figure 2). Because filamentation confers greater sensitivity to
the fungicidal activity of CF, this suggests that both the b-glucan
unmasking activity and fungicidal activity of CF preferentially
affect filamentous cells in vitro.
Direct measurement of baseline b-glucan exposure
during infection with ex vivo immunofluorescence
Our in vitro results point to hyphal-biased activity of CF, but
their relevance for understanding the drug’s activity during
therapy was unclear. We therefore developed a method that
Author Summary
Candida is a common human commensal but disseminat-
ed candidiasis is a serious clinical problem, especially
among immunocompromised patients. The innate im-
mune system controls Candida infection, in part through
the germline-encoded b-glucan receptor Dectin-1. How-
ever, during in vitro growth, Candida albicans mutes
Dectin-1 recognition by cloaking its b-glucan underneath a
layer of mannan. Bridging these two seemingly contradic-
tory observations, we demonstrate that C. albicans masks
b-glucan early during infection, but it becomes exposed
later, allowing Dectin-1 to recognize the fungi and mediate
immunity. Remarkably, treatment of mice with sub-
therapeutic doses of the antifungal drug caspofungin
causes exposure of b-glucan on C. albicans even when it
would not be exposed naturally. We introduce a new
technique for monitoring of epitope exposure during
infection, which can be used to monitor the availability of
any epitope for immune recognition. This technique
allowed us to show that natural unmasking of b-glucan
is not morphotype-specific, but drug-mediated unmasking
is biased towards the invasive filamentous form of C.
albicans. These results highlight the unexplored area of
dynamic epitope exposure during infection and therapy,
which might be targetable to enhance immune recogni-
tion and fungal clearance.
In Vivo Unmasking of b-Glucan
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glucan exposure directly from infected tissue without prior fixation
or sectioning. The fixation and sectioning procedures normally
used to assay cell surface molecules could be misleading as fixation
can itself alter cell surface structure and exposure while sectioning
artificially exposes underlying molecules. In this technique, called
ex vivo fluorescence (EVF), tissue homogenates obtained from
infected animals are washed and whole cells are stained directly
without fixation in order to preserve the live cell wall organization.
Use of WT-GFP C. albicans permitted both the unambiguous
detection of fungi amidst non-fluorescent kidney tissue and the
identification of live fungi based on characteristic fluorescence
pattern (see Methods).
To provide a baseline against which to assay the affects of CF,
the course of b-glucan exposure during disseminated infection in
the absence of CF was measured in BALB/c mice infected
intravenously with WT-GFP Candida. Fungal cells were subse-
quently identified in their kidney homogenates stained by EVF
using a commercially available antibody directed against b-glucan.
As shown in Figure 3A, EVF-stained C. albicans isolated from the
kidney within 16 hours post-infection did not have appreciable b-
glucan exposure (Figure 3A). Similar data were found in heart and
brain homogenates (data not shown). The masking of b-glucan on
Candida at early times post-infection in all cell types suggests that
Dectin-1 plays a minimal role in recognition at this time during
infection.
Figure 1. Caspofungin-mediated unmasking in vitro is filament-biased. (A,B) Wildtype strain CAF2-1 was grown overnight in RPMI-PS with
vehicle (A) or sub-inhibitory doses of CF (B), then stained with anti-b-glucan antibody. Overlays between DIC and anti-b-glucan staining (in red) show
that there is no b-glucan exposure on yeast-form cells, but there are low to high levels of exposure on filaments. (C) Covalent labeling of live yeast-
form cells with Alexafluor 647-succinimidyl ester is homogeneous and bright. (D) Extensive growth in vitro of Alexafluor 647-labeled yeast-form cells
in the presence of serum demonstrates that the label is long-lasting and remains confined to initial yeast-form cell wall. (E) Wildtype strain SC5314-
GFP was pre-labeled with Alexa647, then grown overnight in RPMI-PS with subinhibitory doses of CF (K MIC50). (F–H) Wildtype (F) or nrg1D/D (G) or
edt1D/D (H) mutant cells pre-grown in YPD were washed and diluted into RPMI-PS plus different concentrations of CF; cells grown in K MIC50 of CF
were stained with anti-b-glucan antibody and Cy3-labeled secondary antibody. Images are representative of three independent experiments. Scale
bar shown in panel (A) is 20 microns long for panels (A) and (B) and 10 microns long for (C–H).
doi:10.1371/journal.ppat.1000227.g001
In Vivo Unmasking of b-Glucan
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infection [14], so b-glucan recognition by this receptor might not
normally play a role until later during infection. To discover
whether b-glucan is unmasked later during infection, we infected
mice intravenously with lower doses of WT-GFP C. albicans,
euthanized animals at 1, 3, 5, and 7 days post-infection, and
examined b-glucan exposure by EVF. Remarkably, by five days
post-infection a large percentage of cells had exposed b-glucan
(Figure 3B). The anti-b-glucan antibody is a mouse monoclonal
IgG antibody; however, the control without primary antibody
(Figure 3C) was negative, showing that no detectable host IgG was
bound to the fungus during growth in kidney tissue. In addition to
this control, the robustness of our staining protocol was tested
using different incubation times, omitting the blocking reagent
(bovine serum albumin), and testing two different isotype control
antibodies to ensure this assay does not introduce artifactual
staining (Figures S2, S3, and S4). To quantify the progression in b-
glucan exposure, cells were identified and cell wall-associated b-
glucan fluorescence was quantified as shown in Figure 3D using
the CellProfiler software package [26]. As shown in Figure 3E, the
percentage of cells with b-glucan exposure increases from
approximately 20% to 80% over the time course, demonstrating
time-dependent unmasking of b-glucan during infection.
To assess the cell-type specificity of natural b-glucan unmasking
in vivo, we compared exposure between the yeast-form and hyphal-
form cell wall at early and late points during infection. As shown in
Figure 3F, there was no overall difference in unmasking between
cell forms. Overall, there is very little b-glucan available for
immune recognition in either cell type early during infection but
there is significant exposure of both cell types as infection
progresses. These data demonstrate that, during infection, C.
albicans b-glucan is initially masked from immune recognition, but,
over time, becomes unmasked in a morphotype-independent
fashion.
Caspofungin treatment during C. albicans systemic
infection causes b-glucan unmasking
To determine if treatment of disseminated candidiasis with
caspofungin (CF) could artificially increase b-glucan exposure, we
used different levels of CF to identify a sub-therapeutic dose
(30 mg/kg) that would allow isolation of live fungi that had grown
in the presence of drug (Figure 4A). These concentrations are in
line with those observed to be sub-inhibitory by other investigators
(C. Douglas, pers. comm.) We then infected mice with WT-GFP
Candida, isolated kidneys at 16 hr post-infection when all b-
glucan should be masked, and stained fungi with EVF to look at b-
glucan exposure. Fungi isolated from mice treated with interme-
diate doses of CF had very high levels of b-glucan exposure
(Figure 4D), in contrast to C. albicans isolated from mice treated
with vehicle (Figure 4B). The no-primary-antibody controls
(Figure 4C and 4E) show that this increase is not due to bound
host IgG.
To test if this increase in b-glucan exposure has biological
relevance for immune recognition, we probed with the purified
carbohydrate recognition domain of the b-glucan receptor Dectin-
1 (Dectin1-CRD). As shown in Figure 5, the increased b-glucan
exposure is accompanied by increased availability of b-glucan for
immune recognition (Figure 5). In each of the other types of
experiments presented, Dectin-CRD binding was assayed and
found to mirror antibody binding (data not shown). Thus,
treatment with CF results in exposure of the pro-inflammatory
b-glucan epitope and increased binding to the innate immune
receptor Dectin-1.
To determine whether b-glucan unmasking is a consequence of
treatment with another known anti-fungal compound, we treated
WT-GFP-infected mice with sub-therapeutic doses of either
fluconazole, an anti-fungal drug that targets sterol biosynthesis,
or CF, and then examined b-glucan exposure 16 hours post-
infection (Figure 6). In this experiment, both drug treatments are
active and result in 10-fold decreased fungal burden (Figure 6A)
but only CF treatment causes b-glucan exposure (Figure 6B–6D).
Thus, b-glucan unmasking is specifically associated with CF
treatment and is not a default stage in killing of C. albicans.
b-glucan exposure in vivo preferentially affects the
filamentous cells
The potent b-glucan unmasking activity of caspofungin in vivo
provided a foundation for looking at the morphotype dependence
of b-glucan unmasking during treatment of disseminated infection.
Examination of individual cells for b-glucan exposure due to CF
showed that filament cell walls are exposed, but yeast cell walls are
not (Figure 7A). Quantification with CellProfiler demonstrates the
robustness of this phenomenon, in which filamentous cells stain
with anti-b-glucan whereas yeast-form cells show undetectable
levels of b-glucan exposure (Figure 7B). For Candida isolated from
vehicle-treated mice, neither morphotype showed detectable b-
glucan exposure at these times after infection. Dectin-CRD
binding closely paralleled anti-b-glucan staining for both caspo-
fungin and vehicle treatment (data not shown).
To ensure that this differential effect on filaments was not due to
persistence of the initial inoculum of yeast-form cells, we Alexa
fluor-labeled fungi pre-infection and followed the appearance of
unlabeled yeast-form cells (Figure 7C and 7D). As shown above in
Figure 1, this covalent labeling technique tags cell surfaces with a
long-lasting, non-dispersing mark for following the ancestry of
cells. By three hours post-infection, there was already significant
appearance of unlabeled yeast-form cells, which grew exclusively
post-labeling and therefore post-infection. By six hours, there were
Figure 2. Caspofungin is more effective against filament-
locked mutants than against yeast-locked mutants. Strains were
pre-grown in YPD, washed, sonicated, diluted into RPMI-PS containing
two-fold dilutions of CF, and grown overnight at 30uC to promote both
yeast- and filamentous-form growth. RPMI has phenol red, so yellow
color in the media indicates metabolic activity and acidification of the
media. Changes in color and visual scoring of growth were used to
identify MICs for each strain. Results are representative of four
independent experiments run in duplicate.
doi:10.1371/journal.ppat.1000227.g002
In Vivo Unmasking of b-Glucan
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by 16 hours there were no labeled cells. Notably, at the six hour
time point, the fluorescence of labeled cells was undiminished,
whereas the percentage of labeled cells declined, confirming in vitro
experiments showing that the label is very stable. This quantita-
tively demonstrates that the cells from the initial inoculum are all
cleared by 16 hours post-infection. Therefore, yeast- and hyphal-
form cells examined at 16 hours post-infection all grew in the
presence of the same level of CF and the filament bias in b-glucan
exposure results from the differential action of the drug on
different cell types.
Discussion
A critical goal in understanding both host-pathogen interaction
and drug action is to probe their dynamics during infection. In vivo
experiments show that cell wall b-glucan is a key fungal signature
molecule used by the innate immune system to clear fungal
infection, yet in vitro experiments suggest that Candida albicans masks
b-glucan from immune recognition. To resolve this apparent
paradox, we developed and exploited an ex vivo fluorescence (EVF)
technology to measure the changes in exposure of b-glucan in live
cells during infection. This procedure showed that in the normal
course of infection b-glucan is initially masked but subsequently
exposed on the surface of C. albicans. This reconciles in vitro data
that C. albicans b-glucan is masked by mannoprotein [8,9] with in
vivo infection data suggesting a potential role for Dectin-1 in
immunity to C. albicans. In vivo data with knockout mice is
inconsistent– clearance of the SC5314 strain of C. albicans, used in
this study, from mice in the mixed BL/66129/Sv background, is
dependent on Dectin-1 [14], whereas clearance of a different
strain of C. albicans from mice in the BL/6 background does not
require Dectin-1 for efficient clearance [13]. Taken together, these
data suggest that the Dectin-1 b-glucan receptor plays a role in
resistance to C. albicans in conditions most similar to those used in
our study [14]. Although it is not known how this unmasking
occurs during the course of the infection, it is possible that, with
time, immune cells accumulate in sufficient numbers to directly
damage the cell wall and expose b-glucan. Infiltrating immune
cells may also create an environment that induces physiological
defenses in the fungus, resulting in altered cell wall signaling and
increased exposure of b-glucan. Innate immune cells with the
capacity to damage Candida are recruited to the site of infection in
the first several days of infection, favoring these models [21,27,28].
Alternatively, there may be a novel pathogen-intrinsic pathway
late in infection which is programmed to alter architectural
changes independent of immune function.
EVF also permits unambiguous identification of cellular
morphotype, allowing a rigorous analysis of b-glucan exposure
in yeast vs. hyphal cells. In the absence of drug there is no
difference in exposure of b-glucan between yeast-form and hyphal
cells: both are effectively masked from the immune system early
during infection and both are unmasked later. This provides
evidence that during systemic infection of tissues, filamentous
growth does not allow the fungus to evade recognition by the
Dectin-1 b-glucan receptor. Previous work with in vitro-grown C.
albicans using different media to promote morphotype-specific
growth had suggested that hyphal cells are uniquely immune from
Dectin-1-mediated recognition [9]. However, our in vivo results
show clearly that during infection there is no morphotype-specific
masking or unmasking of b-glucan. This contrast highlights the
critical advantage of looking at the host-pathogen interaction
during infection rather than in vitro.
Treatment of mice with CF during disseminated infection
unmasks C. albicans b-glucan and makes it available for immune
recognition by the Dectin-1 b-glucan receptor. Although unmask-
ing during the normal course of infection shows no morphotype
specificity, CF-mediated unmasking is filament-biased and both b-
glucan unmasking and fungicidal activities of CF are directed
more at filaments than yeast-form cells. The bias may be due to
intrinsic compositional differences between hyphal and yeast wall
[29,30,31,32] or due to differences in transcription of cell wall
regulators sensitive to caspofungin [33]. Filament bias may
contribute to the clinical efficacy of CF by selecting for yeast-
form growth which is less invasive, more easily cleared and
stimulates a more protective immune response [15,20]. The
finding that a particularly effective anti-fungal drug has morpho-
type bias opens the possibility of new anti-fungals designed for
increased effectiveness against the filamentous, invasive form of C.
albicans. The morphotype bias also highlights the potential
shortcomings of using a single growth condition to determine in
vitro drug effectiveness, which can favor one morphotype over
another and fail to reveal such biases.
Figure 3. Candida b-glucan is masked early but unmasked late during disseminated infection. BALB/c mice were infected i.v. tail vein
with 1610
6 (Day 1), 2.5610
5 (Day 3), 1610
5 (Day 5 or 7) organisms of strain SC5314-GFP. Animals were euthanized 1, 3, 5, or 7 days post-infection,
kidneys were isolated, and organisms were stained by EVF for anti-b-glucan with or without primary antibody. (A) Anti-b-glucan staining of hyphae
and yeast-form cells at Day 1 post-infection. Two representative examples are shown. (B) Anti-b-glucan staining of hyphae and yeast-form cells at Day
5 post-infection. Two representative examples are shown. (C) Representative filament from Day 5 post-infection, that the primary antibody was
omitted. (D) Example of cell segmentation and quantification, with arrowhead pointing to yeast-form cell: Left panel is GFP image; center panel
shows different cell segments in different colors; right panel shows the unmodified anti-b-glucan image used for quantification. (E) Categorization of
exposure at different time points post-infection based on quantitative staining measure. No Staining is defined as within 2 standard deviations of the
average fluorescence/cell of cells stained with no primary antibody; Low Staining is defined as cells with average fluorescence/cell greater than 2
standard deviations above, but less than 2-fold above, the average fluorescence of the no primary control; High Staining are cells with fluorescence/
cell greater than two-fold higher than the average of the no primary control. These preparations have a significant amount of highly fluorescent
debris from kidney tissue, which is the likely source of many of the 20% of cells that have ‘‘greater than background’’ levels of staining at the early
time points. (F) Level of b-glucan exposure in hyphal cell wall vs. yeast-form cell wall at 5 to 7 days post-infection. Histogram shows the average
fluorescence/cell for all cells quantified at 5 and 7 days post infection, in comparison to cells stained with no primary anti-b-glucan antibody, as
measured in arbitrary units (a.u.). Error bars show standard error of average fluorescence/cell. All pair-wise comparisons were analyzed by two-tailed
Student’s T-test in Excel (Microsoft Corp.); asterisks indicate statistically significant differences (p,0.01). (G) Overall quantification of b-glucan
exposure in all cells at Days 1, 3, 5, and 7 post-infection, as compared to background staining without primary antibody. All cells from a given day
were pooled, averages and standard error for each group was calculated, and pairwise comparisons were made by two-tailed Student’s T-test in Excel
(Microsoft). Day 1 and Day 3 groups show exposure indistinguishable from the No Primary group (p.0.35 for all pairwise comparisons), and Day 5
and Day 7 groups are indistinguishable from each other (p.0.35), but all comparisons between the two groups show significant differences
(p,0.000001). Comparisons where differences are not significant (p.0.35) are indicated with n.s. and significant comparisons (p,0.000001) are
indicated with three asterisks. Data shown in panels A–G are derived from 12 experiments (Day 1) or 2 experiments each (Days 3, 5, and 7) which were
internally consistent. Scale bar in (A) is 10 microns long and applies to all images.
doi:10.1371/journal.ppat.1000227.g003
In Vivo Unmasking of b-Glucan
PLoS Pathogens | www.plospathogens.org 6 December 2008 | Volume 4 | Issue 12 | e1000227Figure 4. Treatment of C. albicans with caspofungin unmasks b-glucan. BALB/c mice were injected i.p. with caspofungin (CF) or vehicle and
then immediately infected i.v. tail vein with strain SC5314-GFP. 16 hours post-infection, mice were euthanized and kidneys were dissected then
homogenized. (A) Kidney homogenates were assayed for viable colony forming units by broth dilution and plating to YPD agar plates. Bars represent
the average of triplicate plates, and error bars represent standard deviations. (B–E) Kidney homogenates were stained with or without anti-b-glucan
monoclonal antibody and then with Cy3-labeled secondary antibody as described in Materials and Methods. (B,C) SC5314-GFP isolated from mice
treated with vehicle. (D,E) SC5314-GFP isolated from mice treated with 30 mg/kg CF. Images and CFU data are representative of more than 12
experiments using between one and four mice per treatment group. Scale bar in (B) is 10 microns long and applies to all images.
doi:10.1371/journal.ppat.1000227.g004
In Vivo Unmasking of b-Glucan
PLoS Pathogens | www.plospathogens.org 7 December 2008 | Volume 4 | Issue 12 | e1000227Figure 5. Unmasking by caspofungin exposes epitopes recognized by the Dectin-1 b-glucan receptor. Mice were infected and treated as
in Figure 4. At 16 hr post-infection, kidney homogenates were stained with anti-b-glucan antibody followed by Cy3-labeled secondary antibody and
Alexafluor 647-labeled recombinant Dectin-1-CRD. (A) Candida isolated from vehicle-treated mouse (B) Candida isolated from mouse pre-treated with
30 mg/kg CF. Images are representative of more than 6 experiments using between 1 and 3 mice per treatment. Scale bar in (A) is 10 microns long
and applies to all images.
doi:10.1371/journal.ppat.1000227.g005
Figure 6. Fluconazole treatment does not unmask b-glucan. Mice were pre-injected with fluconazole and infected as in Figure 4. At 16 hr
post-infection, kidneys were homogenized. (A) Homogenates were diluted and assayed for viable colony forming units or (B,D) homogenates were
stained with anti-b-glucan monoclonal antibody and Cy3-labeled secondary antibody. Treatments of mice before infection were the following: (B)
single dose of PBS (vehicle), (C) single dose of 2.5 mg/kg fluconazole in PBS, (D) single dose of 30 mg/kg caspofungin in PBS. Images and CFU data are
representative of two independent experiments with 2 to 3 mice per group. Bars in (A) represent averages of triplicate counts and error bars
represent standard deviations. Scale bar in (B) is 10 microns long and applies to all images.
doi:10.1371/journal.ppat.1000227.g006
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PLoS Pathogens | www.plospathogens.org 8 December 2008 | Volume 4 | Issue 12 | e1000227Figure 7. Caspofungin-mediated unmasking in vivo is filament-biased. (A) Two examples in which yeast-form cells have very little exposed
b-glucan, in contrast to the filamentous cell bodies. SC5314-GFP was isolated 16 hr post-infection and stained as above. (B) Quantification of
exposure of hyphae and yeast-form cells in vehicle and CF-treated cases. Images are representative of more than 12 experiments. Quantification
includes data from two independent experiments and includes 133 individual cell segments. Error bars represent standard deviations. All pair-wise
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PLoS Pathogens | www.plospathogens.org 9 December 2008 | Volume 4 | Issue 12 | e1000227Our findings draw attention to a relatively unexplored avenue
for drug development—the identification of drugs that do not
affect the growth or viability of the pathogen per se but render the
pathogen more susceptible to the host immune system. It is likely
that clinical use of CF also causes increased recognition through
the b-glucan receptor, making hyphal cells more susceptible to
immune attack and contributing to the success of the drug. Recent
work shows that caspofungin causes unmasking in other fungal
species and makes them more susceptible to immune attack,
underlining the broad-spectrum robustness of this drug’s activity to
expose b-glucan even in the absence of classical fungicidal activity
[4,6]. Development of new anti-fungal drugs that specifically cause
b-glucan unmasking may reveal novel classes of drugs that target a
non-essential process, provide broad-spectrum clinical protection,
and do not select for resistance in the absence of immune pressure.
Materials and Methods
C. albicans strains and growth conditions
C. albicans strain information is summarized in Table 1. C.
albicans was routinely grown at 37uC in YPD media (DIFCO;
20 g/L peptone, 10 g/L yeast extract) containing 2% glucose. For
infections, C. albicans was washed, counted by hemacytometer, and
diluted to 1*10
7/ml. For MIC experiments, C. albicans was pre-
grown in YPD at 30uC overnight, washed, sonicated briefly with a
Branson sonicator (3610 seconds at setting of 1.5), and diluted
1:100 to a concentration of 2.5*10
6/ml (for WT and yeast-locked
strains) or 1:20 (for hyphal-locked strains that grow poorly) into
RPMI-PS, RPMI (Invitrogen) containing phenol red, sodium
pyruvate, HEPES pH 7.2, with added penicillin-streptomycin.
Caspofungin (Cancidas intravenous formulation, Merck & Co.,
Inc.) was made fresh from lyophilized stock and diluted into
RPMI-PS for in vitro studies or into PBS for intraperitoneal (i.p.)
injection into mice (see below).
Alexa fluor labeling of live C. albicans
For Alexa fluor 647 labeling of C. albicans, cells pre-grown at
37uC overnight in YPD were washed three times in PBS and
resuspended in PBS at a concentration of 1*10
9/ml in 100 ul.
Alexa fluor 647-succinimidyl ester (Molecular Probes) was
dissolved and stored in DMSO at a concentration of 10 mg/ml.
Just prior to labeling, 11 ml of 1 M NaCO3 pH 10 was added to
the Candida and then 2 ml of Alexa fluor 647 was added and mixed
briefly by vortexing. Cells were labeled for 1 hour at room temp,
then washed five times with PBS, counted by hemacytometer, and
used for infection or in vitro experiments. This resulted in no loss of
viability, as assayed by broth dilution and plating to YPD.
Infection and drug treatment of mice
For experiments lasting less than 24 hours, female BALB/c mice
7–10 weeks old were infected with 1*10
6 C. albicans WT-GFP
intravenously (i.v.) through the lateral tail vein. For experiments
lasting more than 24 hours, the following doses were used to
maximize infection burden without morbidity: 2.5*10
5 (Day 3) or
1*10
5(Day 5 or 7).These doses gave kidney burdens within 1 order of
magnitude at the time of euthanization: on days 1, 3, 5, and 7, kidney
burdens averaged respectively 86, 22, 35, and 177 * 10
5 colony
forming units/g tissue. Therefore, the kidney burdens were
comparable but the b-glucan unmasking was dramatically different.
Animals were euthanized with CO2 3 hours to 7 days post-infection,
organs were dissected, and then weighed and homogenized in PBS
with Dounce homogenizers. For colony forming unit assays, organ
homogenates were serially diluted in 10-fold increments in
PBS+penicillin/streptomycin and plated onto YPD plates in
duplicate or triplicate. For drug treatment, 0.1 ml of a 0.6, 6, or
60 mg/ml solution of CF in PBS was injected per mouse i.p. just prior
to tail vein infection, corresponding to doses of 3, 30, or 300 mg/kg.
Alternatively, 0.1 ml of a 0.5 or 5 mg/ml solution of fluconazole
(Sequoia Research Products, United Kingdom) in PBS was injected
Table 1. Strain details.
Strain Name Reference Genotype
SC5314 [35] Wildtype
CAN89 This paper Wildtype, clinical isolate
CAN91 This paper Wildtype, clinical isolate
CAN92 This paper Wildtype, clinical isolate
CAF2-1 [35] ura3D::imm434/URA3
nrg1D/D (MMC3) [24] ura3D::imm434/ura3D::imm434 nrg1D::hisG nrg1D::hisG::URA3::hisG
efg1D/D cph1D/D (HLC54) [25] ura3D::imm434/ura3D::imm434 efg1D::hisG efg1D::hisG cph1D::hisG cph1D::URA3
tup1D/D (BCa2-9) [23] ura3D::imm434/ura3D::imm434 tup1D::hisG tup1D::URA3
WT-GFP This paper Peno1-EGFP_NAT
R
edt1D/D This paper/[36] ura3D::imm434/ura3D::imm434 edt1D::hisG/edt1D::hisG::URA3::hisG
edt1-GFP This paper ura3D::imm434/ura3D::imm434 edt1D::hisG/edt1D::hisG::URA3::hisG Peno1-EGFP_NAT
R
All strains derived from the SC5314 clinical isolate.
doi:10.1371/journal.ppat.1000227.t001
comparisons were analyzed by two-tailed Student’s T-test (Excel, Microsoft Corp.); asterisks indicate statistically significant differences (p#0.0001). (C)
Growth pattern in vivo is similar to in vitro, and proliferation leads to some unlabeled yeast-form cells already by 3 hours post-infection. (D)
Quantification of labeling over time shows that, by 16 hr post-infection, no labeled cells are visible. Quantification includes data from two or three
independent experiments per time point, although 100% labeling efficiency was always confirmed before infection. Scale bar in (A) is 10 microns long
and applies to all images.
doi:10.1371/journal.ppat.1000227.g007
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of 2.5 or 25 mg/kg. All animal experiments were conducted in
accordance with NIH guidelines under IACUC Protocol # 0306-
027-09.
Ex vivo fluorescent staining (EVF)
Dounce-homogenized kidney tissue was washed three times
with PBS, then mammalian cells were lysed with two washes of
distilled water. For washes, cells were spun at 14,0006g for
30 seconds and pellets were vigorously resuspended with vortex-
ing. Homogenates were washed again three times with PBS and
then blocked with 2%BSA in PBS for 1 hour at room temp.
Homogenates were then stained with anti-b-glucan antibody,
specific for b1,3-glucan (Biosupplies, Inc., Australia) diluted 1:200
in 2%BSA/PBS overnight at 4uC on a rotator and washed three
times with PBS. Then homogenates were stained for 1 hour at
room temp with goat anti-mouse Cy3 antibody (Jackson
Immunoresearch) diluted 1:100 into 2%BSA/PBS with or without
Alexa647-labeled Dectin-CRD (diluted 1:40 in 2%BSA/PBS).
The carbohydrate recognition domain of mouse Dectin-1 (Dectin-
CRD) was purified from E. coli and labeled as described previously
[8]. After three washes, cells were visualized by fluorescence
microscopy. Live cells were identified based on characteristic GFP
fluorescence, with cytoplasmic fluorescence excluded only from
vacuoles. Co-staining with propidium iodide shows that the small
proportion of PI-positive cells (,1%) do not have characteristic
GFP fluorescence, and vice versa (data not shown).
Plasmid and C. albicans strain construction
Construction of the pENO1-yEGFP3-NAT plasmid was per-
formed as follows. pENO1GFP3 [22] was digested with KpnI. The
ENO1 locus was amplified from SC5314 genomic DNA with forward
primer (aattggccctgcagatgtcttacgccactaaaatccac) and reverse primer
(aattggccggtaccccagcgtagatagcttcagaacct), which introduce KpnI and
PstI sites, respectively. The NAT1 gene was digested from pJK795
[34] with KpnI and PstI. A triple ligation of these two fragments with
the KpnI-digested pENO1GFP3 resulted in pENO1-yEGFP3-NAT.
EcoRV-digested plasmid was transformed into strain SC5314 by
lithium acetate. Integrants were selected on 100 mg/ml nourseo-
thricin (Werner Bioagents, Jena, Germany) and verified by PCR.
This resulted in the WT-GFP strain, and transformation of the
homozygous deletion strain edt1::hisG/edt1::hisG-URA3-hisG (a deriv-
ative of CAI4) yielded edt1-GFP.
Fluorescence microscopy and Cellprofiler quantification
Samples were visualized with a Nikon TE2000-S microscope
(Nikon, Tokyo, Japan) equipped with Spot RT camera (Diagnostic
Instruments, Sterling Heights, MI, USA) and processed in Photoshop
(Adobe Systems, Palo Alto, CA, USA). In Cellprofiler version
1.0.4884 (www.cellprofiler.org) 12-bit TIFF images of GFP fluores-
cence were used to manually define the edges of individual cell
segments and 12-bit b-glucan fluorescence images without saturate
pixels were used to quantify the average fluorescence intensity for the
whole cell segment. Yeast form cells had a length-width ratio of ,1.5
and characteristic shape and size. Average fluorescence values were
analyzed using JMP 5 statistical software package. For fluorescence
microscopy in supplementary figures, cells were imaged on an
Olympus IX81 inverted microscope with 406 PlanApo objective
using an Orca-ER cooled CCD camera (Hamamatsu Photonics) and
using the IPLab v. 4.04 software package.
Supporting Information
Figure S1 Several clinical isolates also display filament-specific
exposure of b-glucan. Wildtype SC5314 (A–B) and clinical isolates
CAN89 (C–D), CAN91 (E–F) and CAN92 (G–H) were grown
overnight in YPD, washed, and diluted to 4*10
6 cells/ml in fresh
RPMI-PS with different concentrations of caspofungin or vehicle.
After growth overnight at 30uC, cells grown in vehicle (B, D, F,
and H) and at 1/2 MIC50 caspofungin (A, C, E, and G) were
harvested and stained with anti-b-glucan antibody and Cy3-
labeled secondary antibody. Cells were imaged by fluorescence
microscopy and representative images were cropped and pro-
cessed in Photoshop. Scale bar in (A) is 10 microns long and
applies to all images.
Found at: doi:10.1371/journal.ppat.1000227.s001 (2.48 MB TIF)
Figure S2 Altering incubation times during staining procedure
does not alter b-glucan exposure. WT-GFP C. albicans was pre-
grown overnight in YPD, then diluted to 4*10
6 cells/ml and
grown overnight in RPMI-PS media at 30uC with either sub-
inhibitory doses of caspofungin (Caspofungin; A–B, E–F, and I–J)
or vehicle (Vehicle; C–D, G–H, and K–L), then washed with PBS.
Cells were stained with normal length incubations (1 hour block,
overnight primary antibody, 1 hour secondary antibody; A–D),
short incubations (15 minutes block, 15 minutes primary anti-
body, 15 minutes secondary antibody; E–H), or extra-long
incubations (overnight block, 24 hours primary antibody, 1 hour
secondary antibody; I–L). Samples without primary antibody were
used to identify non-specific staining. Cells were imaged by
fluorescence microscopy and representative images were cropped
and processed in Photoshop. Scale bar in (A) is 10 microns long
and applies to all images.
Found at: doi:10.1371/journal.ppat.1000227.s002 (2.67 MB TIF)
Figure S3 Caspofungin exposes b-glucan but does not cause
increased non-specific binding of mouse IgG antibody to C.
albicans. WT-GFP C. albicans was grown overnight in YPD,
washed, and diluted to 4*10
6 cells/ml in fresh RPMI-PS with
different concentrations of caspofungin or vehicle. After growth
overnight at 30uC, cells grown in vehicle (E–H) and at 1/2 MIC50
caspofungin (A–D) were harvested and stained with anti-b-glucan
antibody (Biosupplies, Inc; A and E), isotype control mouse IgG
(Becton Dickinson; B and F), whole mouse IgG control (Santa
Cruz Biotech; C and G) or no primary antibody (D and H) and
Cy3-labeled goat anti-mouse IgG secondary antibody (Jackson
Immunoresearch). Cells were imaged by fluorescence microscopy
and representative images were cropped and processed in
Photoshop. Scale bar in (A) is 10 microns long and applies to all
images.
Found at: doi:10.1371/journal.ppat.1000227.s003 (4.56 MB TIF)
Figure S4 BSA blocking prevents non-specific antibody
binding and doesn’t cause extra b-glucan exposure. WT-GFP
C. albicans was pre-grown overnight in YPD, then diluted to
4*10
6 cells/ml and grown overnight in RPMI-PS media at 30uC
with either sub-inhibitory doses of caspofungin (Caspofungin; A,
C, and E) or vehicle (Vehicle; B, D, and F), then washed with
PBS. (A–B) Cells were stained with a shortened protocol
(30 minutes block, 30 minutes with primary, 15 minutes with
secondary) using buffers including 2% BSA. (C–F) Washed cells
were incubated for 24 hours at 4uC with 2% BSA to determine
if BSA can expose b-glucan. Then, cells were washed and
stained using the shortened protocol with (C–D) or without (E–F)
BSA. Samples without primary antibody were used to identify
non-specific staining. Cells were imaged by fluorescence
microscopy and representative images were cropped and
processed in Photoshop. Scale bar in (A) is 10 microns long
and applies to all images.
Found at: doi:10.1371/journal.ppat.1000227.s004 (4.10 MB TIF)
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